Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 5/20 | 0.39 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 5/20 | 0.37 |
| ▸ | QPCT | Q16769 | 4/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464542 | 0.86 | DYRK1A (0.40) | DYRK1AIDO1PRPS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1050732 | 0.84 | REN (0.42) | DYRK1AIDO1PRPS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13131411 | 0.82 | HTR6 (0.40) | DYRK1AIDO1PRPS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13132161 | 0.80 | ALDH1A1 (0.52) | PRPS1ALDH1A1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL3463638 | 0.80 | MAPT (0.52) | DYRK1APRPS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12048886 | 0.80 | CNR2 (0.55) | ALDH1A1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL19626278 | 0.76 | CNR1 (0.34) | CNR2CNR1SLC6A4GSK3BMAP3K14 | |
| SCHEMBL13132176 | 0.74 | PRPS1 (0.41) | DYRK1AIDO1PRPS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13131399 | 0.74 | IDO1 (0.47) | DYRK1AIDO1ALDH1A1SMN1; SMN2CNR2 | |
| SCHEMBL21816695 | 0.73 | CYP19A1 (0.36) | ALDH1A1SLC6A4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071651-B2 | 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| CN-101268074-B | 5-amino-4-hydroxy-7- (imidazo [1,2-A] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | SPEEDEL EXPERIMENTA AG | 2011-09-21 | — | — | CN | disclosed |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-1948654-B1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| CN-101268074-A | 5-amino-4-hydroxy-7- (imidazo [1,2-A] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2008-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | DYRK1A 1627/4885IDO1 1458/4885PRPS1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.